

Seeking Pulse-release Drug Delivery Platforms

A global health company is seeking one-dose administration **pulse-release drug delivery platforms** for **vaccines and biologics**. Specifically, the team is seeking platforms that **produce an initial burst release**, followed by a **second programmed burst release** that occurs **2-4 weeks following administration**. The platform should have a favourable safety data package including residual and site reactions after the administration and release. The team is interested in **materials and formulations**, provided the platform can deliver a **reproducible, tunable second pulse** in this timeframe while **maintaining biologic integrity and potency**.



Approaches of Interest:

- The delivery platform should be **compatible with whole organism proteins and peptides** or **RNA/ DNA**. Compatibility with **adjuvants** is also sought.
- The platform should be able to be used in **subcutaneous, intramuscular, and in ovo formulation**.
- The stability of the formulation should **maintain activity of the biologic**, including minimizing aggregation and denaturation and addressing potential acidic microclimates caused by polymers.
- The formulation components should be attainable from commercial sources.
- Ideally, materials used for manufacturing of drug product should be regulatory approved with established toxicity profile. Solutions with novel materials are also sought.
- The formulation should be manufactured via a scalable process and sterile/aseptic path, with acceptable excipients and reasonable cost of goods across animal health applications.
- Formulations should be capable of thoroughly characterized, especially the quantification of biological active components.
- If unique device for application is required, please provide details.

Out of Scope:

- Formulations that include materials from animal origin.
- Patch formulations or solutions that require large or expensive equipment to trigger the second pulse.

Developmental Stages of Interest:

- Opportunities should have *in vitro* and *in vivo* data demonstrating pulse timing in the 2-4 weeks window. Encouraged to have animal data.

Submission Information and Opportunity for Collaboration

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions should also include IP information, if available, including a summary of patents (granted or pending), filing jurisdictions. This campaign is open to submissions from SMEs and start-up companies. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations.

Opportunities sought

-  Technologies
-  Biotech assets
-  Research projects

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **10th September 2026 - 10:59 pm GMT**

Have any questions?

Contact our team at campaigns@inpart.io